Skip To Main Content
Laura Bukavina on Muck Rack

Laura Bukavina

As seen in: Nature, Medscape, BioRxiv, MDEdge, European Urology, European Urology Oncology, UroToday, Urologic Clinics of North America, Urology Times, Urology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Laura

Contact Laura, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group

|
By Patrick J. Hensley, Jeremy Y. C. Teoh, Roger Li, Shilpa Gupta, Laura Bukavina, Kent W. Mouw, Niyati Lobo, Brigida Anna Maiorano, Wei Shen Tan, Piyush Agarwal, Hikmat Al-Ahmadie, Trinity J. Bivalacqua, Thomas W. Flaig, Charles C. Guo, Amir Horowitz, Wassim Kassouf, Max Kates, Badrinath R. Konety, Janet B. Kukreja, Yair Lotan, David J. McConkey, Laura Mertens, Maria Carmen Mir, Marco Moschini, Andrea Necchi, Karima Oualla, Vignesh T. Packiam, Bogdana Schmidt, Roger Buckley, Ashish M. Kamat
| Nature Verified
Abstract Crucial unmet needs for standardization and clinical integration of actionable biomarkers persist across the bladder cancer disease spectrum. To address these gaps, the International Bladder Cancer Group (IBCG) convened a global multidisciplinary panel to develop evidence-based consensus recommendations on biomarker use in bladder cancer. Recommendations were formulated across the disease spectrum using a modified Delphi process.
Open in Who Shared Issue with article?

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

|
By Can Aydogdu, Laura Bukavina, Hikmat Al-Ahmadie
| UroToday Verified
Histological subtypes and divergent differentiation are common in bladder cancer. Each subtype has distinct biology and clinical features. We aim to summarize pathology, molecular features, and outcomes of the most common bladder cancer subtypes to guide management.
Open in Who Shared Issue with article?

Emerging Intravesical Therapies for Nonmuscle-Invasive Bladder Cancer

|
By Betty Wang, Ilaha Isali, Adam C. Calaway, Laura Bukavina
| Urologic Clinics of North America Verified
Keywords Nonmuscle-invasive bladder cancer Intravesical therapy BCG-Unresponsive BCG-Naïve UGN-102 Immunotherapy Oncolytic virus Drug delivery systems Get full text access Log in, subscribe or purchase for full access. References 1. Chou, R. ∙ Selph, S. ∙ Buckley, D.I. ... Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis J Urol. 2017; 197(5):1189-1199 2. Babjuk, M. ∙ Burger, M. ∙ Compérat, E.M. ...
Open in Who Shared Issue with article?
See all 22 licensed articles (46 Total)